西班牙急性缺血性卒中患者动脉内骨髓单核细胞移植的安全性与有效性(IBIS试验):一项2期、随机、开放标签、标准治疗对照、多中心试验
IBIS试验在西班牙4个卒中中心纳入77例急性大脑中动脉缺血性卒中患者,随机分为标准治疗对照组(38例)、低剂量骨髓单核细胞(BMMNC)组(20例,2×10^6/kg)和高剂量组(19例,5×10^6/kg)。主要疗效终点180天mRS 0-2比例在各BMMNC组与对照组间均无显著差异;动脉内BMMNC安全,但未显著改善180天mRS。
要点
- 急性缺血性卒中发病1-7天内动脉内注射自体BMMNC安全,未增加不良事件。
- 低剂量组180天mRS 0-2比例为50%,对照组39%,校正OR 2.08(95%CI 0.55-7.85),p=0.28。
- 高剂量组180天mRS 0-2比例44%,校正OR 1.89(95%CI 0.52-6.96),p=0.33。
核心结论
- 动脉内BMMNC在急性缺血性卒中患者中是安全的,但180天mRS未见显著改善。
- 需要进一步临床试验来探究是否在不同时间点可能获得改善。
研究设计与样本
- IBIS试验为多中心2期、随机、对照、研究者发起、评估者盲法临床试验,在西班牙4个卒中中心开展。
- 纳入年龄18-80岁、非腔隙性大脑中动脉缺血性卒中、发病1-7天内、NIHSS评分6-20分的患者。
- 按2:1:1随机分配至标准治疗对照组或动脉内注射自体BMMNC两个剂量组之一(2×10^6/kg或5×10^6/kg);共随机77例:对照组38例、低剂量组20例、高剂量组19例。
主要发现
- 主要疗效终点180天mRS 0-2比例:对照组14例(39%)vs 低剂量组10例(50%),校正OR 2.08(95%CI 0.55-7.85),p=0.28。
- 高剂量组180天mRS 0-2比例8例(44%),校正OR 1.89(95%CI 0.52-6.96),p=0.33;汇总BMMNC组18例(47%),校正OR 2.22(95%CI 0.72-6.85),p=0.16。
- 不良事件或剂量相关事件比例无差异,但低剂量BMMNC组有2例患者在细胞注射后出现腹股沟血肿。
- 患者平均年龄62.4岁(SD 12.7),46例(60%)为男性,31例(40%)为女性,均为白人,63例(82%)接受了取栓治疗;随机化前NIHSS评分中位数12分(IQR 9-15),动脉内BMMNC注射在卒中发病后中位6天(4-7天)进行。
局限性
- 需要进一步临床试验来探究是否在不同时间点可能获得改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pilot clinical trials have shown the safety of intra-arterial bone marrow mononuclear cells (BMMNCs) in stroke. However, the efficacy of different doses of intra-arterial BMMNCs in patients with acute stroke has not been tested in a randomised clinical trial. We aimed to show safety and efficacy of two different doses of autologous intra-arterial BMMNC transplantation in patients with acute stroke. METHODS: The IBIS trial was a multicentre phase 2, randomised, controlled, investigator-initiated, assessor-blinded, clinical trial, in four stroke centres in Spain. We included patients (aged 18-80 years) with a non-lacunar, middle cerebral artery ischaemic stroke within 1-7 days from stroke onset and with a National Institutes of Health Stroke Scale score of 6-20. We randomly assigned patients (2:1:1) with a computer-generated randomisation sequence to standard of care (control group) or intra-arterial injection of autologous BMMNCs at one of two different doses (2 × 106 BMMNCs/kg or 5 × 106 BMMNCs/kg). The primary efficacy outcome was the proportion of patients with modified Rankin Scale scores of 0-2 at 180 days in the intention-to-treat population, comparing each BMMNC dose group and the pooled BMMNC group versus the control group. The primary safety endpoint was the proportion of serious adverse events. This trial was registered at ClinicalTrials.gov, NCT02178657 and is completed. FINDINGS: Between April 1, 2015, and May 20, 2021, we assessed 114 patients for eligibility. We randomly assigned 77 (68%) patients: 38 (49%) to the control group, 20 (26%) to the low-dose BMMNC group, and 19 (25%) the high-dose BMMNC group. The mean age of participants was 62·4 years (SD 12·7), 46 (60%) were men, 31 (40%) were women, all were White, and 63 (82%) received thrombectomy. The median NIHSS score before randomisation was 12 (IQR 9-15), with intra-arterial BMMNC injection done a median of 6 days (4-7) after stroke onset. The primary efficacy outcome occurred in 14 (39%) patients in the control group versus ten (50%) in the low-dose group (adjusted odds ratio 2·08 [95% CI 0·55-7·85]; p=0·28), eight (44%) in the high-dose group (1·89 [0·52-6·96]; p=0·33), and 18 (47%) in the pooled BMMNC group (2·22 [0·72-6·85]; p=0·16). We found no differences in the proportion of patients who had adverse events or dose-related events, but two patients had a groin haematoma after cell injection in the low-dose BMMNC group. INTERPRETATION: Intra-arterial BMMNCs were safe in patients with acute ischaemic stroke, but we found no significant improvement at 180 days on the mRS. Further clinical trials are warranted to investigate whether improvements might be possible at different timepoints. FUNDING: Instituto de Salud Carlos III co-funded by the European Regional Development Fund/European Social Fund, Mutua Madrileña, and the Regional Ministry of Health of Andalusia.
引用
- Moniche F, Cabezas-Rodriguez JA, Valverde R, et al. Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial. Lancet Neurol. 2023. PMID: 36681446. doi:10.1016/S1474-4422(22)00526-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。